Nearly 30% of women diagnosed with early-stage breast cancer will go on to develop metastatic disease, which is when the cancer can spread to another part of the body, months or even years after the original diagnosis and treatment. At Menarini Stemline, we believe it is crucial

The Menarini Stemline team is feeling inspired after joining METAvivor in Washington D.C. at their annual Stage IV Stampede earlier this week. We are proud to help bring metastatic breast cancer to national healthcare policy conversations. #BreastCancerAwarenessMonth

Breast cancer represents 25% of all cancers in women. At Menarini Stemline we are proud to continue to raise awareness, while we work relentlessly to develop and deliver new treatments to support the individuals and families impacted by breast cancer. #BreastCancerAwarenessMonth

What a great start to Breast Cancer Awareness Month! This past weekend, the Menarini Stemline team connected with patient advocates at the National Black Breast Cancer Summit, hosted by the Sisters Network. It was a great conference with advocates convening from all over the

October marks the start of Breast Cancer Awareness Month. This month serves as a crucial reminder of why our Menarini Stemline team remains driven to find new options for the individuals living with metastatic breast cancer. #BreastCancerAwarenessMonth #mBCAwareness

Today, Rare Cancer Day, we shine a light on the critical need for continued research and awareness for less common, yet equally devastating, cancers. One such ultra-rare hematologic malignancy is Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). BPDCN is an aggressive cancer

Today marks World Cancer Research Day, a moment to recognize the critical role of scientific discovery in the fight against cancer. Join us in honoring the brilliant minds dedicated to advancing the forefronts of science and conquering cancer! #WorldCancerResearchDay

Did you know that Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), an aggressive and challenging hematologic malignancy, is more common in elderly patients, with a median onset age between 60 and 70 years? We are committed to addressing the unique needs of patients facing

This Blood Cancer Awareness Month, we're shedding light on a rare and aggressive hematologic malignancy: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). BPDCN is an ultra-rare cancer, with a global prevalence estimated at approximately 12 cases per 100,000 individuals. its

Today, on World Leukemia Day, we join the global community in raising awareness for leukemia, a group of cancers that impact blood-forming tissues. Leukemia is a significant global health challenge, with over 470,000 new cases diagnosed around the world each year. At Menarini

This September, Menarini Stemline proudly joins the global community in recognizing Blood Cancer Awareness Month. Blood cancer remains the fifth most common type of cancer worldwide, impacting millions of lives. At Menarini Stemline, we're dedicated to advancing scientific

Happy Labor Day from Menarini Stemline! Today, we recognize the unwavering dedication and hard work of our entire Menarini Stemline team. We also extend our sincere gratitude to all workers across our communities whose contributions build, strengthen, and innovate. Thank you for

Today on World Breast Cancer Research Day, we stand with the global scientific community, recognizing the critical role of research in bringing hope and progress to those impacted by breast cancer. At Menarini Stemline, we are proud to contribute to this vital work, striving for

Our Bridgewater, NJ team took a break from the conference rooms to enjoy a great summer BBQ last week! It was a fantastic opportunity to relax, connect, and celebrate our hard work and achievements together. #MenariniStemline

Today we are wishing our U.S.-based followers a safe and happy Fourth of July! #IndependenceDay

Our team had an energizing few days in Chicago at #ASCO25! We are looking forward to continuing to collaborate with leaders in the oncology community and continuing our work to transform cancer care for patients.

Today we are proud to recognize the 18.1 million+ cancer survivors in the U.S. The team at Menarini Stemline is committed to providing innovative options to the cancer community today, and every day. #NCSD2025

The Menarini Stemline team is in Chicago this week to join the oncology community at #ASCO25. If you’re onsite, be sure to visit our booths to learn more about our focus on bringing transformational oncology treatments to individuals living with cancer.

The Menarini Stemline team is in Chicago this week to join the oncology community at #ASCO25. If you’re onsite, be sure to visit our booths to learn more about our focus on bringing transformational oncology treatments to individuals living with cancer.

Today we join the global #bloodcancer community to raise awareness of all blood cancers, including BPDCN, a rare, aggressive, hematologic malignancy. Learn more at https://t.co/90gfF2VKcH. #WorldBloodCancerDay